Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(4R)-4-([(2S)-2-acetamido-3-carboxypropanoyl]amino)-5-([(2R,3S)-1-([(2S)-1-[(2S,4R)-4-(benzyloxy)-2-(2-([(1S)-1-(4-bromophenyl)ethyl]carbamoyl)-2-propylhydrazinecarbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino)-3-methyl-1-oxopentan-2-yl]amino)-5-oxopentanoic acid | noncovalent binding to enzyme active site, 50% inhibition at 0.000072 mM | Hepacivirus C | |
(4R)-4-([(2S)-2-acetamido-3-carboxypropanoyl]amino)-5-([(2R,3S)-1-([(2S)-1-[(2S,4R)-4-(benzyloxy)-2-(2-([(1S)-2,3-dihydro-1H-inden-1-yl]carbamoyl)-2-propylhydrazinecarbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino)-3-methyl-1-oxopentan-2-yl]amino)-5-oxopentanoic acid | noncovalent binding to enzyme active site, 50% inhibition at 0.0001 mM | Hepacivirus C | |
(4R)-4-([(2S)-2-acetamido-3-carboxypropanoyl]amino)-5-([(2R,3S)-1-([(2S)-1-[(2S,4R)-4-(benzyloxy)-2-(2-butyl-2-([(1S)-1-phenylethyl]carbamoyl)hydrazinecarbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino)-3-methyl-1-oxopentan-2-yl]amino)-5-oxopentanoic acid | noncovalent binding to enzyme active site, 50% inhibition at 0.000099 mM, over 400fold selectivity for enzyme over human leukocyte elastase | Hepacivirus C | |
(4R)-4-([(2S)-2-acetamido-3-carboxypropanoyl]amino)-5-([(2S,3S)-1-([(2S)-1-[(2S,4R)-4-(benzyloxy)-2-(2-ethyl-2-([(1S)-1-phenylethyl]carbamoyl)hydrazinecarbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino)-3-methyl-1-oxopentan-2-yl]amino)-5-oxopentanoic acid | noncovalent binding to enzyme active site, 50% inhibition at 0.000085 mM | Hepacivirus C | |
(4R)-4-[[(2S)-2-(acetylamino)-3-carboxypropanoyl]amino]-5-[(1-[[(1R)-1-([(2S,4R)-4-(benzyloxy)-2-[(2-[[(1S)-1-phenylethyl]carbamoyl]-2-propylhydrazino)carbonyl]pyrrolidin-1-yl]carbonyl)-2-methylpropyl]carbamoyl]-2-methylbutyl)amino]-5-oxopentanoic acid | noncovalent binding to enzyme active site, 50% inhibition at 0.000078 mM | Hepacivirus C |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Hepacivirus C | - |
- |
- |